CVBT to begin clinical trial into diabetic wounds
15th Sep 2005, 03:55 GMT
CardioVascular BioTherapeutics has received the green light from the FDA to commence its phase I clinical trial in diabetic patients who have foot ulcers and/or open leg wounds.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol